Figure 4.

CX3CR1 expression on circulating monocyte subsets in patients with RA at baseline and over anti-TNFα treatment. The mean fluorescence intensity (MFI) of CX3CR1 in circulating CD14+highCD16- (panel A), CD14+highCD16+ (panel B) and CD14+lowCD16+ monocytes (panel C) of non-responders (□) and responders (○) at baseline and after three and six months of MTX treatment, as well as those of healthy controls (▼), are shown as means ± SEM. Panel D is a histogram of CX3CR1 for circulating CD14+highCD16- monocytes from a representative responder and non-responder at six months of treatment. * Significant difference between patients and healthy controls. † Significant difference between non-responders and responders. ‡ Significant difference between baseline and six-month values.

Chara et al. Arthritis Research & Therapy 2012 14:R175   doi:10.1186/ar3928
Download authors' original image